Evidence map›Paper›PMID 41992978›Full record

ArticleOncology reports2026

Perturbation of BRD4 and p300 activity suppresses super enhancer‑driven

Nurul Nadia Mohamad Zamberi, Asmaa Y Abuhamad, Siti Nur Hasanah Mohd Yusuf, Nur Qurratu Athirah A Rahman, Mohamad Aimanuddin Mohtar, Saiful Effendi Syafruddin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nurul Nadia Mohamad ZamberiUniversiti Kebangsaan Malaysia Medical Molecular Biology Institute, Cheras, Kuala Lumpur 56000, Malaysia.
Asmaa Y AbuhamadFaculty of Health and Life Sciences, Management and Science University, Shah Alam, Selangor 40100, Malaysia.
Siti Nur Hasanah Mohd YusufUniversiti Kebangsaan Malaysia Medical Molecular Biology Institute, Cheras, Kuala Lumpur 56000, Malaysia.
Nur Qurratu Athirah A RahmanUniversiti Kebangsaan Malaysia Medical Molecular Biology Institute, Cheras, Kuala Lumpur 56000, Malaysia.
Mohamad Aimanuddin MohtarUniversiti Kebangsaan Malaysia Medical Molecular Biology Institute, Cheras, Kuala Lumpur 56000, Malaysia.
Saiful Effendi SyafruddinUniversiti Kebangsaan Malaysia Medical Molecular Biology Institute, Cheras, Kuala Lumpur 56000, Malaysia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Super enhancers (SEs) are involved in regulating cell identity and lineage‑specific gene expression, and drive cancer‑associated gene expression. The transcription factor Kruppel‑like factor 6 (KLF6) promotes the growth and progression of clear cell renal cell carcinoma (ccRCC), with its high expression driven by one of the strongest SEs in ccRCC. However, the mechanisms that establish and maintain

Indexed as

Carcinoma, Renal CellCell Cycle ProteinsE1A-Associated p300 ProteinKidney NeoplasmsKruppel-Like Factor 6Transcription FactorsAcetylationAzepinesBromodomain Containing ProteinsCell Line, TumorCell ProliferationCell SurvivalGene Expression Regulation, NeoplasticHeterocyclic Compounds, 4 or More RingsHumansSuper EnhancersA-485 compoundAzepinesBRD4 protein, humanBromodomain Containing ProteinsCell Cycle ProteinsE1A-Associated p300 ProteinEP300 protein, humanHeterocyclic Compounds, 4 or More Rings(+)-JQ1 compoundKLF6 protein, humanKruppel-Like Factor 6Transcription FactorsTriazolesepigenetic modifierKruppel‑like factor 6 (KLF6)renal carcinomasuper enhancertranscription factor

Identifiers

PMID41992978
PMCPMC13107101

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.